Provided by Tiger Trade Technology Pte. Ltd.

Vertex Pharmaceuticals

456.20
+8.821.97%
Post-market: 455.90-0.3000-0.07%19:40 EST
Volume:5.56M
Turnover:2.53B
Market Cap:115.75B
PE:32.08
High:460.40
Open:446.86
Low:445.51
Close:447.38
52wk High:519.68
52wk Low:362.50
Shares:253.72M
Float Shares:253.72M
Volume Ratio:4.20
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.22
EPS(LYR):-2.0768
ROE:22.31%
ROA:12.04%
PB:6.68
PE(LYR):-219.67

Loading ...

Is CASGEVY’s Pediatric Breakthrough And Priority Review Altering The Investment Case For Vertex (VRTX)?

Simply Wall St.
·
Yesterday

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Dec 20

Post-AI Rally: Four Defensive Stocks to Watch for 2026

Stock News
·
Dec 19

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Dec 18

Vertex Pharmaceuticals (VRTX): Valuation Check After Positive Pediatric CASGEVY Data and Priority FDA Review Voucher

Simply Wall St.
·
Dec 17

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Dec 11

Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating

MT Newswires Live
·
Dec 10

Vertex Pharmaceuticals Incorporated : Wells Fargo Raises Target Price to $515 From $460

THOMSON REUTERS
·
Dec 10

Vertex 1H Net Y1.44B Vs Net Y1.45B

Dow Jones
·
Dec 10

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Dec 09

Disney, Nu Holdings, Phillips 66 And A Health Care Stock On CNBC's 'Final Trades'

Benzinga
·
Dec 08

Vertex's Gene Therapy Works In Children With Blood Disorders

Benzinga
·
Dec 08

Reassessing Vertex Pharmaceuticals After Pipeline Progress and Recent 7% Share Price Jump

Simply Wall St.
·
Dec 08

Vertex Minerals Says New South Wales Gold Mine Underground Loader Loads Ore from Stope by Remote Control

MT Newswires Live
·
Dec 08

Vertex (VERX): Valuation Check After Expanded AI Tax Compliance Partnership With CPA.com

Simply Wall St.
·
Dec 07

Vertex Unveils Positive CASGEVY Data in Children and Plans Global Submissions

Reuters
·
Dec 06

Vertex Presents New Data on Casgevy®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

THOMSON REUTERS
·
Dec 06

Vertex Pharmaceuticals: Presents New Data on Casgevy, Including First-Ever Data in Children Ages 5-11 Years

THOMSON REUTERS
·
Dec 06

Vertex: Consistent With Studies in Older Patients, Children Treated With Casgevy Have Durable Increases in Fetal Hemoglobin & Stable Allelic Editing

THOMSON REUTERS
·
Dec 06

Vertex's gene therapy shows promise in younger children with blood disorders

Reuters
·
Dec 06